Skip to main
TVTX

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 38%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics has demonstrated strong commercial execution, particularly with the easing of Risk Evaluation and Mitigation Strategy (REMS) requirements, which is anticipated to enhance prescriber adoption of its product FILSPARI. The acceleration of sparsentan sales and progress in the Japanese regulatory pathway solidify its potential as a foundational therapy for IgA nephropathy, strengthening the company's position in a competitive market. Additionally, the cancellation of the Advisory Committee meeting and the favorable stock response underscore positive developments that could further benefit Travere’s market standing and financial performance.

Bears say

The negative outlook on Travere Therapeutics's stock is informed by significant uncertainties regarding its clinical trial outcomes, which may jeopardize the progression of its therapeutic candidates through development. Additionally, recent FDA actions, including leadership changes and shifting review practices, have created an environment of increased scrutiny in the biotech sector, heightening investor apprehension. Furthermore, the company could face challenges in securing adequate funding necessary to support its drug development initiatives, compounding the risks associated with its ongoing projects.

Travere Therapeutics (TVTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 13 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.